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THE MORAL INTERCEPTION OF ORAL 
CONTRACEPTION: POTENTIAL 
CONSTITUTIONAL CLAIMS AGAINST THE 
FDA’S PRESCRIPTION REQUIREMENT FOR 






In its July/August 2012 issue, The Atlantic magazine named an 
over-the-counter birth control pill one of the “Biggest Ideas of the 
Year.”1 In actuality, the idea of making an oral contraceptive 
available over the counter is far from novel.2 In 1993, The 
American Journal of Public Health published an editorial asserting 
“safety and compliance concerns are no longer sufficient to justify 
maintaining the current clinical control over a woman’s 
contraceptive selection.”3 The editorial went on to declare that “[a] 
national dialogue on [the issue of over-the-counter oral 
contraceptives] is overdue.”4 Twenty years later, the unavailability 
of a daily over-the-counter oral contraceptive has the growing 
                                                          
* J.D. Candidate, Brooklyn Law School, 2014; B.J., University of Nebraska-
Lincoln, 2011. I would like to thank my family and friends, especially Tex 
Richters, Judy Garlock, and Kelsey Richters, for their encouragement and 
reassurance. I would also like to thank the Journal of Law and Policy staff for 
all of their help in preparing the note for publication. 
1 The Ideas Report, ATLANTIC (July 2012), 
http://www.theatlantic.com/special-report/ideas-2012/; Nicole Allan, Sell  
the Pill Over the Counter, ATLANTIC (June 13, 2012), 
http://www.theatlantic.com/magazine/archive/2012/07/sell-the-pill-over-the-
counter/308997/. 
2 See, e.g., James Trussell et al., Should Oral Contraceptives Be Available 
Without Prescription?, 83 AM. J. PUB. HEALTH 1094 (1993). 
3 Id. 
4 Id. 
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potential to generate a meritorious constitutional claim implicating 
the right to privacy and embedded right to use contraception.   
While the idea of an over-the-counter birth control pill is not 
new, there has undoubtedly been a recent resurgence in the 
movement for such a contraceptive option.5 For example, in a 2012 
Committee Opinion, the American College of Obstetricians and 
Gynecologists (ACOG), the largest association of OB/GYNs in the 
country, announced its support for the sale of over-the-counter oral 
contraceptives.6 The American Medical Association (AMA) 
followed suit.7 During its 2013 annual meeting, the AMA adopted 
a resolution recommending “that manufacturers of oral 
contraceptives be encouraged to submit the required application 
and supporting evidence for the [Food and Drug Administration 
(FDA)] to consider approving a switch in status from prescription 
to over-the-counter for such products . . . .”8  
Additionally, recent cases such as Tummino v. Von 
                                                          
5 See, e.g., Margaret Wente, Drop the Paternalism and Sell the  
Pill over the Counter, GLOBE & MAIL (Mar. 20, 2012, 2:00 AM), 
http://www.theglobeandmail.com/commentary/drop-the-paternalism-and-sell-
the-pill-over-the-counter/article536144/. FDA-approved birth control methods 
can be divided into several classes. FDA, OFFICE OF WOMEN’S HEALTH, Birth 
Control Guide, available at http://www.fda.gov/downloads/ForConsumers/ 
ByAudience/ForWomen/FreePublications/UCM356451.pdf (listing various 
kinds of oral contraception and how they are used).  These classes include 
“Barrier Methods,” “Hormonal Methods,” “Emergency Contraception,” 
“Implanted Devices,” and “Permanent Methods.” A daily birth control pill is a 
hormonal method of contraception. Both the estrogen-progestin combination 
oral contraceptive as well as the progestin-only variety are currently FDA-
approved but are available only with a doctor’s prescription. Id.   
6 AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS, COMM. ON 
GYNECOLOGIC PRACTICE, COMM. OP. NO. 544, OVER-THE-COUNTER ACCESS TO 
ORAL CONTRACEPTIVES 1–3 (2012), available at http://www.acog.org/~/ 
media/Committee%20Opinions/Committee%20on%20Gynecologic%20Practice
/co544.pdf. See also Abby Ohlheiser, OB/GYNs Back Over-The-Counter Birth 




 Annual Meeting Memorial Resolutions, Am. Med. Ass’n (June 2013), at 
464 [hereinafter AMA Resolutions], available at http://www.ama-
assn.org/assets/meeting/2013a/a13-resolutions.pdf.   
8  Id. 
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Eschenbach9 and Tummino v. Hamburg10 suggest that the current 
movement for expanded contraceptive access has made its way to 
the courts. In Hamburg, plaintiffs initially brought action in 2005 
challenging the FDA’s decision to deny a citizen petition11 
requesting that all women, regardless of age, have over-the-counter 
access to emergency contraception.12 Judge Edward R. Korman 
presided over the Hamburg case. He found that the FDA’s denial 
of the citizen petition for over-the-counter emergency 
contraception rested on unusual actions, deviations from policy, 
and the unprecedented involvement of the Health and Human 
Services (HHS) Secretary Kathleen Sebelius.13   
Judge Korman ultimately instructed the FDA to “make 
levonorgestrel-based emergency contraceptives14 available [to 
                                                          
9  Tummino v. Von Eschenbach, 427 F. Supp. 2d 212 (E.D.N.Y. 2006). 
10 Tummino v. Hamburg, 936 F. Supp. 2d 162 (E.D.N.Y. 2013).  
11 A citizen petition can be filed with the FDA requesting that the Agency 
“issue, amend, or revoke a regulation or order or take or refrain from taking any 
other form of administrative action.” 21 C.F.R. § 10.25 (2010). “A Citizen 
Petition may be filed at anytime” and  “must contain certain things such as 
clearly stating what the Petitioner is asking the FDA to do and a statement of 
grounds for the request.  After the Petition is filed, anyone can file comments 
about it, and the Dockets Management Branch will then send the Petition and 
any comments to the appropriate divisions within FDA for resolution.” The 
Petition Process, FDA PETITIONS, http://www.fdapetitions.com/process.html 
(last visited Nov. 2, 2013).  
12 Hamburg, 936 F. Supp. 2d at 165. See also 21 C.F.R. § 310.200(b) 
(2010) (“A proposal to exempt a drug from the prescription-dispensing 
requirement of section 503(b)(1)(C) of the act may be initiated by the 
Commissioner or by any interested person. Any interested person may file a 
[Citizen] [P]etition seeking such exemption . . . .”). “Emergency contraception, 
or emergency birth control, is used to help keep a woman from getting 
pregnant after she has had sex without using birth control or if the birth control 
method failed.” Emergency Contraception (Emergency Birth Control) Fact 
Sheet, OFFICE ON WOMEN’S HEALTH, http://www.womenshealth 
.gov/publications/our-publications/fact-sheet/emergency-contraception.cfm#a 
(last updated Nov. 2, 2011).  
13 Hamburg, 936 F. Supp. 2d at 169–71. 
14 Levonorgestrel “is a progestin hormone that prevents pregnancy by 
preventing the release of an egg (ovulation) and changing the womb and cervical 
mucus to make it more difficult for an egg to meet sperm (fertilization) or attach 
to the wall of the womb (implantation).” Levonorgestrel Oral, WEBMD, 
http://www.webmd.com/drugs/drug-17833-levonorgestrel+oral.aspx (last visited 
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women of all ages] without a prescription . . . .”15 Judge Korman 
further stated that the FDA did not have the authority to require 
that Plan B16 “be sold only at pharmacies and health clinics and 
that it be kept behind the counter” as had been its practice.17 This, 
he held, constituted an impermissible point-of-sale restriction on 
the distribution of emergency contraception.18 Though the decision 
to ban age and point-of-sale restrictions on the sale of Plan B 
concerned emergency contraception rather than a daily birth 
control pill (“the pill” or “birth control pill”), it indicates the 
potential for judicial involvement in the FDA’s future decisions 
concerning contraceptive access.  
While there is strong support for expanded access to 
contraception, there are staunch opponents to an over-the-counter 
daily birth control pill.19 The Catholic Medical Association, for 
example, ardently opposes the ACOG’s recommendation to make 
birth control pills available over the counter.20 Catholic 
obstetricians and gynecologists (OB/GYNs) largely cite safety 
concerns as their reason for opposition, although one St. Louis 
OB/GYN, Dr. Richard Brennan, reasoned that “[e]asier access to 
the pill means more people taking the pill, and in turn, a higher 
number of contraceptive failure. As we know, greater than [fifty] 
percent of abortions today are a result of contraceptive failures.”21 
Opponents also have financial reasons to oppose an over-the-
counter birth control pill.22 For example, since pap smears are now 
                                                          
Nov. 2, 2013).  
15 Hamburg, 936 F. Supp. 2d at 197. 
16 Plan B is a brand of emergency contraception. About, PLAN B ONE-STEP, 
http://www.planbonestep.com/about-plan-b-one-step.aspx (last visited Nov. 3, 
2013). 
17 Hamburg, 936 F. Supp. 2d at 180, 183. 
18 Id. at 183. 
19 See, e.g., Jennifer Brinker, Easier Access? Statement Pushing Over-the-
Counter Access to the Pill Leaves Some Wondering How it Truly Benefits 
Women, ST. LOUIS REV. (Dec. 19, 2012), http://stlouisreview.com/ 
article/2012-12-19/easier-access. 
20 Id. 
21 Id.  
22 See Elisabeth Rosenthal, Is It Time for Off-the-Shelf Birth-Control Pills?, 
N.Y. TIMES (Apr. 20, 2013), http://www.nytimes.com/2013/04/21/sunday-
review/is-it-time-for-off-the-shelf-birth-control-pills.html (discussing arguments 
 MORAL INTERCEPTION OF ORAL CONTRACEPTION 397 
recommended once every three years, many young women see 
their gynecologists every year just to obtain birth-control 
prescriptions.23 Therefore, if women could obtain the pill over the 
counter, they would visit their gynecologists less frequently, 
resulting in a financial loss for the gynecologist.24 Moreover, 
whether it be to curry favor with constituents like the religious 
groups and medical professionals described above, or to simply 
make their own views public, some politicians have recently 
expressed opposition to expanded access to birth control.25 
Therefore, certain medical professionals, religious groups, and 
politicians oppose an over-the-counter pill for a myriad of reasons. 
Though reproductive rights advocates or other interested 
parties have not yet submitted a citizen petition requesting that a 
daily birth control pill be switched from prescription to over-the-
counter status,26 proponents of such a switch have initiated a 
dialogue with the FDA.27 For example, on March 23, 2012, the 
FDA held a public hearing entitled, Using Innovative Technologies 
and other Conditions of Safe Use to Expand Which Drug Products 
Can Be Considered Nonprescription.28 At the hearing, several 
presenters urged FDA panelists to consider making a daily 
hormonal birth control pill available without a prescription.29 
Daniel Grossman, Assistant Clinical Professor of Obstetrics and 
Gynecology at the University of California at San Francisco, 
                                                          
that drug companies and gynecologists could lose business as a result of women 
gaining easier access to birth-control pills). 
23 Id.  
24 Id.  
25 See, e.g., Nick Baumann, The Republican War on Contraception, 
MOTHER JONES (Feb. 9, 2012), http://www.motherjones.com/politics/2012/02/ 
republican-war-birth-control-contraception.   
26 See, e.g., AMA Resolutions, supra note 7, at 464 (recommending that an 
equivalent manufacturer’s application be filed).  
27 See FOOD & DRUG ADMIN., CTR. FOR DRUG EVALUATION & RES., FDA-
2012-N-0171, USING INNOVATIVE TECHNOLOGIES AND OTHER CONDITIONS OF 
SAFE USE TO EXPAND WHICH DRUG PRODUCTS CAN BE CONSIDERED 
NONPRESCRIPTION 7, 37 (2012) [hereinafter FDA Public Hearing  
2012], available at http://www.fda.gov/downloads/Drugs/NewsEvents/ 
UCM301940.pdf. 
28 Id at 1.  
29 See id. at 38–52.  
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presented at the hearing.30 During his presentation, Grossman told 
panelists that despite the safety and popularity of oral 
contraceptives, the high rate of unintended pregnancies indicates 
that the prescription requirement may impose a significant barrier 
to access for some women.31 
According to Grossman and other proponents of an over-the-
counter birth control pill, a progestin-only32 oral contraceptive 
would be the most likely candidate for initial over-the-counter 
availability.33 Because progestin-only oral contraceptives do not 
contain estrogen, these birth control pills have fewer 
contraindications than their estrogen-progestin combination 
counterparts.34 Despite the safety of progestin-only oral 
contraceptives, the FDA, as evidenced by its treatment of 
emergency contraception, is unlikely to hurry to make a daily 
hormonal birth control pill available over the counter. Deviations 
from policy, including “intolerable delays,” surrounded the FDA’s 
actions with respect to the petition for unrestricted access to over-
                                                          
30 Id. at 41. Grossman also serves as the coordinator of the Oral 
Contraceptives Over-the-Counter Working Group, a privately funded coalition 
of scientists, doctors, and reproductive justice advocates who are currently in the 
process of evaluating the viability of an over-the-counter oral contraceptive. Id. 
at 41–42.  
31 Id. 
32 A progestin-only oral contraceptive is sometimes called the “mini-pill” 
because, unlike combination pills that contain estrogen and progestin, the mini-
pill contains only progestin. Progestin-Only Contraceptives, FAMILY DOCTOR, 
http://familydoctor.org/familydoctor/en/prevention-wellness/sex-birth-
control/birth-control/progestin-only-contraceptives.html (last visited Oct. 18, 
2013). “The Mini-Pill affects the mucus around the cervix and makes it harder 
for sperm to enter the uterus. It also affects the transport of the egg through the 
fallopian tubes. In these ways, the Mini-Pill prevents fertilization.” Mini-Pills, 
FEMINIST WOMEN’S HEALTH CTR., http://www.feministcenter.org/health-
wellness-services/comprehensive-gyn/birth-control-options/birth-control-
information/101-mini-pills (last visited Oct. 17, 2013).  
33 See Progestin-Only Pill Eyed as OTC OC Candidate, 33 
CONTRACEPTIVE TECH. UPDATE 52, 52 (2012). 
34 Progestin-Only Contraceptives, supra note 32. A contraindication is a 
patient condition that makes a medication unadvisable for use. Definition of 
Contraindication, MEDTERMS, http://www.medterms.com/script/main/art.asp? 
articlekey=17824 (last visited Oct. 18, 2013). 
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the-counter emergency contraception.35 Further, there was 
unprecedented involvement by the Secretary of Health and Human 
Services that marked the “first time a cabinet member had ever 
publicly countermanded a determination by the F.D.A. . . .”36  
After the FDA initially agreed to approve an application from Plan 
B’s manufacturer to make the product available over the counter 
without age restrictions, the HHS Secretary ordered the FDA 
Commissioner to deny the application.37 Though the Secretary’s 
“political interference”38 applied to the manufacturer’s application 
and not the pending citizen petition, her directive “made it 
impossible as a practical matter for the FDA to approve the Citizen 
Petition” that relied on the same data as the manufacturer’s 
application.39 Though the FDA won’t likely replicate these 
deviations from policy to delay a hypothetical citizen petition for a 
daily over-the-counter oral contraceptive, given its history with 
emergency contraception, it is unlikely that the FDA will decide to 
initiate actions to make a daily birth control pill available over the 
counter.  
The FDA has not yet been compelled to make a decision or 
take action with regard to an over-the-counter daily birth control 
pill because advocates have yet to submit a petition or application. 
Without a final agency action sufficient to subject the decision to 
judicial review, plaintiffs are unable to bring a constitutional claim. 
However, should the FDA take official action and deny an over-
the-counter daily birth control pill, then a substantive due process 
or equal protection claim challenging the constitutionality of the 
prescription requirement would be possible. The constitutionally 
recognized right to contraception and the value placed on gender 
equality in American society bolster the viability of such a claim. 
Additionally, the safety of the progestin-only pill, the availability 
of new technology to dispense medicines over the counter, and 
mounting public policy considerations serve as practical 
justifications for the elimination of the prescription requirement.   
                                                          
35 Tummino v. Hamburg, 936 F. Supp. 2d 162, 198 (E.D.N.Y. 2013). 
36 Id. at 170.  
37 Id. at 167.  
38 Id. at 170.  
39 Id. at 169.  
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The FDA’s maintenance of the prescription requirement for a 
progestin-only birth control pill has the potential to generate a 
meritorious substantive due process or equal protection violation 
claim. Part I of this Note examines the prevalence of unintended 
pregnancies in the United States, discusses the ways in which the 
prescription requirement acts as a barrier to contraceptive access 
for some women, and finally suggests that, based on the 
availability of new technology, a progestin-only pill is safe for 
over-the-counter sale. Part II discusses the FDA and the criteria the 
Agency uses to switch a medication from prescription to over-the-
counter status. Part III assumes arguendo that the FDA’s 
maintenance of the prescription requirement would be subject to 
judicial review and assesses the viability of a substantive due 
process violation claim and an equal protection violation claim 
challenging the prescription requirement for a progestin-only pill.  
 
I. UNINTENDED PREGNANCY, BARRIERS TO ACCESS, AND THE 
SAFETY OF THE PILL  
 
A. Prevalence of Unintended Pregnancies in the United States  
 
Nearly half of all pregnancies in the United States are 
unintended.40 Whether unwanted or mistimed, minority women, 
young women, and low-income women have the highest rates of 
these unintended pregnancies.41 While a significant number of 
unintended pregnancies end in abortion, many do not.42 Births 
from unwanted pregnancies can be problematic for the child, the 
                                                          
40 Facts on Unintended Pregnancy in the United States, FACT SHEET 
(Guttmacher Inst., New York, N.Y.), Oct. 2013, at 1, 1–2 [hereinafter Facts on 
Unintended Pregnancy], available at http://www.guttmacher.org/pubs/FB-
Unintended-Pregnancy-US.pdf. 
41 Id. at 1.  
42 Facts on Induced Abortion in the United States, IN BRIEF (Guttmacher 
Inst., New York, N.Y.), Oct. 2013, at 1, 1 [hereinafter Facts on Induced 
Abortion], available at http://www.guttmacher.org/pubs/fb_induced_abortion 
.pdf (“[A]bout four in [ten]” unintended pregnancies “are terminated by abortion 
. . . . Twenty-two percent of all pregnancies (excluding miscarriages) end in 
abortion.”). 
 MORAL INTERCEPTION OF ORAL CONTRACEPTION 401 
mother, and society at large.43  
Unintended pregnancies often produce negative consequences 
for both the mother and the child. Women who experience 
unintended pregnancies and choose to give birth are less likely to 
breastfeed, less likely to receive timely prenatal care, and are more 
likely to smoke during their pregnancies.44 Substantial research 
indicates that women who experience unplanned pregnancies are 
more likely than women who planned their pregnancies to 
experience depression and other mental health problems both 
during their pregnancies and after giving birth.45 In addition, 
“unintended births have implications for the child that last from 
early childhood through adolescence and even into adulthood.”46 
For example, children born as a result of an unintended pregnancy 
“have poorer physical health than those whose births were 
intended,” may be “less successful in school,” and, according to 
one study, are at an increased risk of child abuse.47 Studies also 
indicate that the majority of teen pregnancies are unintended.48 
“Daughters of teen mothers are three times more likely to become 
teen parents themselves than girls born to older moms.”49 
Moreover, “sons born to young teens are significantly more likely 
to be incarcerated.”50  
                                                          
43 See Jennifer McIntosh et al., Changing Oral Contraceptives from 
Prescription to Over-the-Counter Status: An Opinion Statement of the Women’s 
Health Practice and Research Network of the American College of Clinical 
Pharmacy, 31 PHARMACOTHERAPY 424, 424 (2011). 
44 William D. Mosher et al., Intended and Unintended Births in the United 
States: 1982–2010, NAT’L HEALTH STATS. REPS., no. 55, July 24, 2012, at 1, 13. 
45 Cassandra Logan et al., The Consequences of Unintended Childbearing: 
A White Paper, CHILD TRENDS, INC., May 2007, at 8, available at 
http://www.thenationalcampaign.org/resources/pdf/consequences.pdf. 
46 Id. at 5.  
47 Id. at 6, 7. 
48 See Lawrence B. Finer & Mia R. Zolna, Unintended Pregnancy in the 
United States: Incidence and Disparities, 2006, 84 CONTRACEPTION 478, 481 
(2011). 
49 Kari Huus, A Baby Changes Everything: The True Cost of Teen 
Pregnancy’s Uptick, NBC NEWS (Feb. 19, 2010), 
http://www.nbcnews.com/id/35448556/ns/us_news-the_elkhart_project/t/baby-
changes-everything-true-cost-teen-pregnancys-uptick. 
50 Id.  
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Apart from the negative consequences for mothers and 
children, unplanned pregnancies result in economic costs to the 
public.51 In 2006, public funds totaling more than $11 billion paid 
the medical expenses for more than two-thirds of the births 
resulting from unintended pregnancies.52 In 2008, the cost of each 
birth paid for by Medicaid averaged $12,613, while the 
contraceptive costs for each patient would have averaged only 
$257.53 Therefore, every dollar invested in contraceptives saves 
$3.74 in Medicaid expenses.54 One study evaluated the short-term 
monetary public savings of unintended pregnancy prevention 
through California’s Medicaid family planning project.55 The 
authors estimated that by averting approximately 205,000 
unintended pregnancies, the public saved more than $1 billion 
within the two years following the prevented pregnancies.56 
Additionally, eliminating the prescription requirement for oral 
contraceptives would save money on unnecessary medical care. 
The IMS Institute for Healthcare Informatics estimates that more 
than $200 billion was spent on unnecessary health services in 
2009.57 Incidentally, a blood pressure screening and a breast exam 
are the “only physical examination steps pertinent to 
contraindications of oral contraceptives.”58 Because high blood 
pressure is only a contraindication for the estrogen-progestin 
                                                          
51 McIntosh et al., supra note 43.  
52 See Adam Sonfield et al., The Public Costs of Births Resulting from 
Unintended Pregnancies: National and State-Level Estimates, 43 PERSP. 
SEXUAL & REPROD. HEALTH 94, 98–99 (2011). 
53 Policy Brief: Key Points about Contraception, BRIEFLY (Nat’l Campaign 
to Prevent Teen & Unplanned Pregnancy, Washington, D.C.), Sept. 2012, at 1, 
2, available at http://www.thenationalcampaign.org/resources/pdf/ 
Briefly_PolicyBrief_FactsAboutContraception.pdf. 
54 Id.  
55 See Gorette Amaral et al., Public Savings from the Prevention of 
Unintended Pregnancy: A Cost Analysis of Family Planning Services in 
California, 42 HEALTH SERVICES RES.  1960 (2007). 
56 Id. at 1962, 1970.  
57 Tara Parker-Pope, Too Much Medical Care?, N.Y. TIMES WELL BLOG 
(July 25, 2012, 12:20 PM), http://well.blogs.nytimes.com/2012/07/25/too-much-
medical-care.   
58 Trussell et al., supra note 2, at 1095.   
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combination pill and not a progestin-only pill,59 a breast exam 
would be the sole physical examination relevant to 
contraindications of progestin-only pills.60  The American Cancer 
Society recommends that the average woman under forty years old 
have a clinical breast exam only every three years.61 Additionally, 
pap smears are now recommended only every three years by the 
American Congress of Obstetricians and Gynecologists.62 
Therefore, some women may be forced to undergo unnecessary 
screenings during at least some of their annual exams simply to 
obtain a prescription for a birth control pill. Allowing women to 
forgo unnecessary doctor’s appointments, pelvic exams, and other 
screenings that are conducted before a woman can obtain a 
prescription for birth control would significantly reduce medical 
costs.63 Eliminating the prescription requirement for at least some 
types of oral contraceptives, such as a progestin-only pill, could 
reduce total expenditures related to unnecessary medical care.64   
Nonuse and gaps in contraceptive use, particularly those gaps 
resulting from lapses in birth control prescriptions, are among the 
primary causes of unintended pregnancies.65 Indeed, though only 
                                                          
59 Daniel Grossman, Oral Contraceptives and Conditions of Safe Over-the-
Counter Use, OCS OTC WORKING GRP. (Mar. 23, 2012) [hereinafter  
Grossman, Oral Contraceptives], available at http://ocsotc.org/wp-
content/uploads/2012/03/Grossman-OTC-public-hearing-presentation-23-Mar-
12.pdf. 
60 See Trussell et al., supra note 2, at 1095.   
61 American Cancer Society Guidelines for the Early Detection of Cancer, 
AM. CANCER SOC’Y, http://www.cancer.org/healthy/findcancerearly/ 
cancerscreeningguidelines/american-cancer-society-guidelines-for-the-early-
detection-of-cancer (last modified May 3, 2013). 
62 Announcement, New Cervical Cancer Screening Recommendations from 
the U.S. Preventative Services Task Force and the American Cancer 
Society/American Society for Colposcopy and Cervical Pathology/American 
Society for Clinical Pathology, Am. Cong. of Obstetricians & Gynecologists 
(Mar. 14, 2012), http://www.acog.org/About_ACOG/Announcements/ 
New_Cervical_Cancer_Screening_Recommendations.aspx [hereinafter New 
Cervical Cancer Screening Recommendations].   
63 See Stephanie Mencimer, Holding Birth Control Hostage, MOTHER 
JONES (Apr. 30, 2012), http://www.motherjones.com/politics/2012/04/ 
doctors-holding-birth-control-hostage.   
64 Id.  
65 See FDA Public Hearing 2012, supra note 27, at 47. 
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sixteen percent of women who are at risk of experiencing an 
unintended pregnancy do not use any form of contraception for a 
month or more during the year, these women account for fifty-two 
percent of all unintended pregnancies.66  
 
B. Prescription Requirement as a Barrier to Access  
 
The birth control pill is the most popular method of hormonal 
contraception.67 However, there are barriers that prevent many 
women, especially minority, young, and low-income women—
groups with the highest rates of unplanned pregnancies—from 
obtaining the pill.68 A number of women report difficulty accessing 
or using methods of birth control as a reason for their nonuse.69  
Access issues vary greatly among women.70 For example, 
uninsured and low-income women may find it difficult to afford a 
visit to a primary care physician and in turn, be unable to obtain a 
prescription for a birth control pill.71 In one national survey, 
women who used or wanted to use a prescription contraceptive 
cited the long wait to get a doctor’s appointment, inconvenient 
office hours, the high cost of seeing a physician, and the pelvic 
exam requirement—which incidentally does not screen for 
contraindications to the pill72—as top obstacles in accessing 
                                                          
66 Facts on Unintended Pregnancy, supra note 40, at 4. 
67 Daniel Grossman, Should the Contraceptive Pill Be Available Without 
Prescription?, 338 BRIT. MED. J., Jan. 24, 2009, at 202, 202 [hereinafter 
Grossman, Contraceptive Pill]. 
68 See FDA Public Hearing 2012, supra note 27, at 41–42; Barriers to 
Contraceptive Access for Low-Income Women, QUICK SHEET (Nat’l Inst. for 
Reprod. Health, New York, N.Y.) [hereinafter Barriers to Contraceptive 
Access], available at http://www.nirhealth.org/sections/publications/ 
documents/contraceptiveaccessquicksheetFINAL.pdf. 
69 Jennifer J. Frost et al., Improving Contraceptive Use in  
the United States, IN BRIEF (Guttmacher Inst., New York, N.Y.),  
Apr. 2008, at 3, available at http://www.guttmacher.org/pubs/2008/05/09/ 
ImprovingContraceptiveUse.pdf. 
70 See Barriers to Contraceptive Access, supra note 68. 
71 Id.  
72 Felicia H. Stewart et al., Clinical Breast and Pelvic Examination 
Requirements for Hormonal Contraception: Current Practice vs. Evidence, 285 
J. AM. MED. ASSOC. 2232, 2232 (2001).    
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prescription oral contraceptives.73 In the same survey, forty-one 
percent of nonusers indicated that they would be more likely to use 
a patch, vaginal insert, or the pill if it were available without a 
prescription.74 One reason for this may be that young women are 
concerned about their parents becoming aware of their use of 
contraception through the insurers’ billing practices.75 This 
concern may affect not only teens, but also young adult women 
given that individuals up to age twenty-six may remain on their 
parents’ insurance plans.76 Based on the plethora of barriers to 
contraceptive access and the privacy issues involved, it is not 
surprising that young women, uninsured women, and current oral 
contraceptive users alike have a strong interest in an over-the-
counter oral contraceptive.77  
Federally mandated contraceptive coverage without co-
payments through the Patient Protection and Affordable Care Act 
(PPACA) fails to address all the barriers to access that women may 
face. Many barriers, as discussed above, are not directly associated 
with cost.78 Moreover, some women will not be covered under the 
PPACA, including those women who are undocumented 
immigrants, and women whose insurance plans will be 
grandfathered into the new system and will be exempt from the 
contraceptive coverage mandate.79 Moreover, churches and places 
of worship with religious objections are exempt from the 
contraceptive mandate and are thus not required to pay for their 
                                                          
73 FDA Public Hearing 2012, supra note 27, at 42. 
74 Id.  
75 Michelle Andrews, How Some Parents Could Learn Adult Daughters’ 
Birth Control Habits, NPR (Oct. 2, 2012, 10:54 AM), http://www.npr.org/ 
blogs/health/2012/10/02/162145030/how-some-parents-could-learn-adult-
daughters-birth-control-habits. 
76 Id.  
77 The Oral Contraceptives Over-the-Counter Working Group conducted a 
survey and found that young women, uninsured women, and current 
contraceptive users were interested in an over-the-counter pill.  See FDA Public 
Hearing 2012, supra note 27, at 42. 
78 See Amanda Dennis et al., Moving Oral Contraceptives Over-the-
Counter: Frequently Asked Questions about What We Know and What We Still 
Need to Know, OCS OTC WORKING GRP., http://ocsotc.org/?page_id=7 (last 
updated Aug. 2013). 
79 See id. 
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female employees’ birth control prescriptions.80  
Because PPACA eliminates the cost barrier for a significant 
number of women, ensuring that oral contraceptive costs are kept 
low if they are indeed switched to over-the-counter status is 
extremely important to ensure increased access to the pill.81 
Though PPACA only requires coverage for prescription 
contraceptives, eliminating the prescription requirement would 
save women the cost of doctor’s visits, save time, and increase 
convenience in obtaining oral contraceptives.82 Additionally, 
commentators have argued that insurance companies should be 
required to provide coverage for Plan B, over-the-counter 
emergency contraception.83 This coverage, they argue, would 
allow women who are unable to afford the over-the-counter retail 
price of Plan B to obtain the time-sensitive emergency 
contraceptive sooner because they would no longer need a 
prescription simply to get insurance coverage.84 Similar requests 
for insurance coverage would likely be made when a daily birth 
control pill is available over the counter. Even if insurance is not 
required to cover an over-the-counter pill, the elimination of the 
prescription requirement allows women to choose to pay for the 
pill out-of-pocket in order to save the time and expense associated 
with a doctor’s visit.85 Thus, although PPACA lowers the cost of 
contraceptives for a significant number of American women, 
eliminating the prescription requirement for progestin-only pills is 
necessary to give women more options for obtaining birth control. 
Further, an over-the-counter option for birth control pills would 
address the non-monetary barriers associated with oral 
                                                          
80 See Abigail Rubenstein, Obama Announces Compromise on Birth 
Control Rule, LAW360 (Feb. 10, 2012), http://www.law360.com/articles/ 
308543/obama-announces-compromise-on-birth-control-rule. 
81 See Dennis et al., supra note 78. 
82 Id.  
83 Britt Wahlin, Viewpoint: Why Birth Control Needs to Be Both Over the 
Counter and on Your Insurance Plan, THINKPROGRESS (Apr. 30, 2013, 12:00 
PM), http://thinkprogress.org/health/2013/04/30/1934631/viewpoint-birth-
control-otc/. 
84 Id.  
85 See Barriers to Contraceptive Access, supra note 68. 
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contraceptive access.86  
 
C.  A Progestin-Only Pill Could Be Safely Dispensed Over the 
Counter Using New Technology  
 
In 1960, the FDA approved the birth control pill for 
contraceptive use.87 Since then, it has generally been regarded as 
very safe.88 Based on its lower prevalence of contraindications, a 
progestin-only pill, as opposed to an estrogen-progestin 
combination pill, is the most likely candidate for initial over-the-
counter approval.89 Progestin-only oral contraceptives are ninety-
six percent effective at preventing pregnancy and work by 
thickening the mucus around a woman’s womb while 
simultaneously thinning the womb’s lining.90 This makes it 
difficult for sperm to enter and for an egg to attach to the lining.91 
Progestin-only pills sometimes prevent the release of an egg 
altogether, much like an estrogen-progestin combination oral 
contraceptive.92 Though perhaps slightly less effective at 
preventing pregnancy than estrogen-progestin combination pills, 
progestin-only pills are safer for smokers, individuals with high 
blood pressure, those prone to clotting abnormalities, and women 
who have a family history of heart attack or stroke.93 Indeed, 
Hamburg approved an emergency contraceptive pill containing the 
progestin levonorgestrel for over-the-counter sale without age or 
                                                          
86 See Dennis et al., supra note 78. 
87 Alexander Nikolchev, A Brief History of the Birth Control Pill, PBS 
(May 7, 2010), http://www.pbs.org/wnet/need-to-know/health/a-brief-history-of-
the-birth-control-pill/480/. 
88 See, e.g., Grossman, Contraceptive Pill, supra note 67, at 202; Trussell et 
al., supra note 2, at 1095.    
89 See Progestin-Only Pill Eyed as OTC OC Candidate, supra note 33. The 
progestin-only pill “very slightly increases the risk of ectopic pregnancy” and 
users may experience irregular bleeding. Mini-Pills, supra note 32.  
90 Progestin-Only Contraceptives, supra note 32; Understanding the 
Minipill, BIRTH, http://www.birth.com.au/Sex-and-contraception/Minipill? 
p=1 (last updated Dec. 28, 2012). 
91 Progestin-Only Contraceptives, supra note 32. 
92 See id. 
93 Understanding the Minipill, supra note 90. 
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point of sale restrictions.94 Levonorgestrel is also used in many 
daily progestin-only oral contraceptives.95 
Besides preventing pregnancy, progestin-only birth control 
pills also have health benefits.96 Extensive research indicates that 
the progestin-only birth control pill regulates the menstrual cycle, 
lowers the risk of anemia, and decreases the “risk of endometrial 
cancer and pelvic inflammatory disease.”97 In addition to improved 
physical health, women may benefit from using birth control in 
other ways.98 A University of Michigan study, though not specific 
to progestin-only pills, found that women who begin taking 
hormonal birth control pills at an early age are more likely to have 
higher paying careers later in their lives than women who begin 
taking the pill at an older age.99 The reason, according to the study, 
is that “[a]s the Pill provided women with cheaper and more 
effective control over childbearing in late adolescence, they 
invested more in their human capital and careers.”100  
Several studies have shown that women are able to take a daily 
birth control pill safely without physician involvement.101 In 
determining whether to write a prescription for an oral 
contraceptive, a physician relies mostly on a patient’s medical 
history.102 Unsurprisingly, research shows that women who 
obtained oral contraception after a doctor’s visit were no less likely 
to have contraindications to the pill than those women who 
obtained the pill directly from a pharmacy.103 In a study examining 
                                                          
94 See Tummino v. Hamburg, 936 F. Supp. 2d 162, 197 (E.D.N.Y. 2013). 
95 FDA Public Hearing 2012, supra note 27, at 39, 41. 
96 See Mini-Pills, supra note 32.  
97 Id. 
98 See Birth Control Access Boosts Women’s Wages, Study Finds, 
HUFFINGTON POST  (Mar. 26, 2012, 2:07 PM), http://www.huffingtonpost 
.com/2012/03/26/birth-control-access-womens-wages_n_1380250.html. 
99 Id.  
100 Martha J. Bailey et al., The Opt-in Revolution? Contraception and the 
Gender Gap in Wages 26 (Nat’l Bureau of Econ. Research, Working Paper No. 
17922, 2012), available at http://www.nber.org/papers/w17922.pdf? 
new_window=1. 
101 See, e.g., Grossman, Contraceptive Pill, supra note 67, at 202–03. 
102 Trussell et al., supra note 2, at 1095.  
103 Grossman, Contraceptive Pill, supra note 67, at 202–03. In Mexico, 
where women can obtain oral contraceptives over-the-counter, women who get 
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women’s continued use of oral contraceptives, discontinuing the 
pill was more common among women who obtained the 
contraceptive via a doctor’s prescription than those who acquired 
the pill over the counter.104 The findings, the researchers suggest, 
indicate that “removing the prescription requirement for [oral 
contraceptive pills (OCPs)], in addition to making it easier for 
women to initiate OCP use, would not have an adverse impact on 
continuation and might well improve it.”105 
Emerging technology could be used to increase access to the 
pill and improve efficiency in dispensing an oral contraceptive 
over the counter.106 At the FDA’s 2012 public hearing, Elizabeth 
Dawes, a senior associate with the non-profit Reproductive Health 
Technologies Project, explained that technology could improve the 
distribution of oral contraceptives.107 According to Dawes, the 
improved efficiency will be necessary given that more individuals 
will likely seek medical care after receiving insurance coverage 
through PPACA.108 During her presentation, Dawes described new 
technology such as “electronic kiosks, retail clinics, and self-
dispensing machines” that are currently being developed to 
dispense contraceptives.109 She explained that research shows these 
methods of access “to be acceptable and appropriate for clients 
willing to forego an in-person consultation with the clinical 
provider.”110 Dawes even said that for patients who would like 
professional guidance in their decision to use oral contraceptives, 
technology could be used to increase convenience.111 As Dawes 
                                                          
the pill over-the-counter are no more likely to experience side effects than 
women who had a doctor’s appointment before using the pill. Id. at 202. 
104 Joseph E. Potter et al., Continuation of Prescribed Compared With 
Over-the-Counter Oral Contraceptives, 117 OBSTETRICS & GYNECOLOGY 551, 
551 (2011). The study compared 514 women who obtained over-the-counter 
pills in Mexico and 532 women who obtained prescription birth control pills in 
El Paso, Texas. Id.  
105 Id. at 556.  
106 FDA Public Hearing 2012, supra note 27, at 39. 
107 See id. at 38–39. 
108 Id. at 38. 
109 See id. at 39.  
110 Id.   
111 Id.  
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asserted, the “expanded use of telephone or provider-to-patient 
video interface” has been shown to be effective at producing both 
patient satisfaction and positive health outcomes while 
simultaneously lowering the cost of health care.112  
This type of technology could improve the safe distribution of 
an over-the-counter birth control pill.113 Dr. Eleanor Schwarz, the 
Director of Women’s Health Research for the Center for Research 
on Health Care at the University of Pittsburgh, presented at the 
same hearing.114 Schwarz described a study in which computerized 
kiosks were programmed to screen for all of the World Health 
Organization’s identified contraindications to birth control pills 
containing estrogen.115 The kiosk featured text in both English and 
Spanish and provided an audio option for individuals with 
restricted literacy.116 The kiosk provided information about seven 
methods of contraception and women, after learning about these 
methods, had the option to request a prescription.117 Upon this 
request, the kiosk asked women questions designed to screen them 
for contraindications to the method they had selected.118 If the 
kiosk determined that the method was safe for the particular 
woman, it printed a prescription, which also included the screening 
information.119 The patient then gave this information to a health 
care provider who would fill the prescription after checking the 
patient’s blood pressure.120  
Most women who used the kiosk had a positive experience 
with the system.121 Women who used the kiosk reported that it 
provided them with trustworthy information and was easy to 
                                                          
112 Id.  
113 See id. at 47.  
114 Id.  
115 Id. at 48.  
116 Id.  
117 Id.  
118 Id.  
119 Id.  
120 Id. The blood pressure screening was done because hypertension is a 
contraindication to the estrogen-progestin combination pill. Hypertension is not 
a contraindication to a progestin-only oral contraceptive. See Grossman, Oral 
Contraceptives, supra note 59.   
121 See FDA Public Hearing 2012, supra note 27, at 48. 
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understand and use.122 The success of the kiosk system led 
Schwarz and her team to conduct additional research.123 Using a 
sample of more than 800 women in four different health care 
settings, half were randomly assigned to the contraceptive kiosk.124 
Minority women, women with low levels of education, and women 
who hadn’t used a method of contraception during their last 
intercourse—groups with high rates of unintended pregnancies—
were especially likely to seek prescriptions after using the 
kiosks.125  
As indicated by extensive research and the low prevalence of 
contraindications, progestin-only oral contraceptives are generally 
accepted as safe.126 Indeed, as discussed above, a progestin-only 
pill, albeit an emergency contraceptive variety, is already available 
over the counter.127 Further, because physicians heavily rely on the 
medical history provided by the patient herself in determining 
whether or not to prescribe a progestin-only birth control pill, a 
doctor’s involvement in a woman’s decision to use this method of 
oral contraception is generally unnecessary.128 Technology that is 
in development or already available could be used to aid in the 
efficient and safe distribution of a daily progestin-only pill.129 
Though the kiosk system described above would be expensive to 
install widely, it provides an example of how emerging technology 
could work to carefully dispense an already safe drug to those who 
need it. The FDA typically uses labeling to safely distribute over-
the-counter drugs,130 and the same would certainly be done for a 
                                                          
122 Id.  
123 Id.  
124 Id. at 48–49.  
125 Id. For example, “fifty-seven percent of women who requested 
contraceptive prescriptions reported they’d had one or more episode of 
unprotected sex in the last month.” Id. at 49.  
126 See Trussell et al., supra note 2, at 1095. 
127 Tummino v. Hamburg, 936 F. Supp. 2d 162, 197 (E.D.N.Y. 2013). 
128 Trussell et al., supra note 2, at 1095.   
129 See FDA Public Hearing 2012, supra note 27, at 39, 48. 
130 See Hamburg, 936 F. Supp. 2d at 180. (“The FDA’s willingness to rely 
on labeling to make [‘Alli, a weight-loss drug that is likely to attract teenage 
purchasers’ and ‘cough syrup containing dextromethorphan, which is regularly 
abused by teenagers,’ for example] available for sale over-the-counter without 
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birth control pill when it is made available over the counter. 
Therefore, whether it be through a high-tech kiosk or the FDA’s 
more traditional labeling approach, a progestin-only oral 
contraceptive could be safely dispensed over the counter.   
 
II. THE FDA AND CRITERIA FOR A PRESCRIPTION TO OVER-THE-
COUNTER SWITCH  
 
On June 30, 1906, Congress passed the Food and Drug Act.131 
Approved by President Theodore Roosevelt, the Act banned states 
from buying or selling mislabeled or tainted drugs, food, and 
drinks.132 The Federal Food, Drug, and Cosmetic Act (FDCA), 
passed in 1938, required that new drugs meet a threshold level of 
safety before they were approved by the FDA.133 In 1951, the 
Durham-Humphrey Amendment to the FDCA required that any 
“habit-forming or potentially harmful [drug] . . . be dispensed 
under the supervision of a health practitioner as a prescription 
drug.”134  
The FDA is permitted to exempt drugs from the prescription 
requirement when the Agency determines that such a requirement 
is “not necessary for the protection of the public health.”135 Drugs 
can be fully or partially switched from prescription to over the 
counter status or a new drug can be directly classified as over the 
counter.136 Because the FDA has not set forth a rigid test to 
                                                          
any age or point-of-sale restrictions, even though they are unsafe for 
unsupervised use by young adolescents, stands in stark contrast to its refusal to 
make equally available concededly safe and time-sensitive levonorgestrel-based 
emergency contraceptives.”).  
131 History of the FDA and Drug Regulation in the United States, FDA, at 
1, available at http://www.fda.gov/downloads/Drugs/ResourcesForYou/ 
Consumers/BuyingUsingMedicineSafely/UnderstandingOver-the-
CounterMedicines/ucm093550.pdf. 
132 Id.  
133 Id. at 2.  
134 This Week in FDA History - Oct. 26, 1951, FDA, 
http://www.fda.gov/AboutFDA/WhatWeDo/History/ThisWeek/ucm117875.htm 
(last updated May 20, 2009).  
135 21 U.S.C. § 353 (2012).  
136 Regulation of Nonprescription Drug Products, FDA, available at 
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM148055.
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determine whether a prescription drug should be made available 
over the counter, drugs are made available without a prescription 
on an ad hoc basis.137 There are, however, several criteria that are 
traditionally applied in making such a determination.138 Factors 
used in the FDA’s determination include: (1) whether or not the 
drug has significant toxicity in the event of an overdose, (2) 
whether the drug is addictive, (3) whether users are able to “self-
diagnose conditions for appropriate use,” (4) whether users are 
able to take the medication safely without a medical professional’s 
screening, and (5) whether users are able to take the drug as 
directed without the explanation of a healthcare provider.139   
Progestin-only birth control pills easily satisfy the first three 
factors. Birth control pills are not significantly toxic in the event of 
an overdose, are not addictive,140 and, as previously discussed, 
women are able to self-diagnose their own need to use oral 
contraception.141 Research indicates that the remaining two factors 
could also be satisfied.142 Recent studies and events illustrate that 
women can safely use progestin-only contraceptives without a 
doctor’s screening. This is evidenced by the availability of 
technology that could be used to screen for contraindications and 
studies that reveal that women obtaining progestin-only pills over 
the counter are no more likely to experience adverse reactions than 
women who obtained the contraceptive with a prescription.143 The 
final factor, the ability to take medicine without the explanation of 
a healthcare provider, could be met with clear and informative 
labeling as well as with new technology such as the kiosks 
discussed above.144 Therefore, a progestin-only birth control pill 
can effectively meet each of the factors the FDA considers in 
                                                          
pdf. 
137 See, e.g., Lars Noah, Treat Yourself: Is Self-Medication the Prescription 
for what Ails American Health Care?, 19 HARV. J.L. & TECH. 359, 366–67 
(2006). 
138  Grossman, Oral Contraceptives, supra note 59.  
139 Id.  
140 FDA Public Hearing 2012, supra note 27, at 42. 
141 Id. 
142 See id. at 43. 
143 See id. at 43, 48. 
144 See McIntosh et al., supra note 43, at 433. 
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determining whether a drug should be made available over the 
counter.  
 
III. POTENTIAL CONSTITUTIONAL CHALLENGES TO THE 
PRESCRIPTION REQUIREMENT FOR A PROGESTIN-ONLY BIRTH 
CONTROL PILL  
 
In order to consider potential constitutional claims, several 
requirements with regard to procedure must first be met. The first 
requirement is that the FDA Commissioner puts forth an 
exemption proposal, a drug sponsor files the requisite 
supplemental drug application, or a citizen group submits a petition 
to switch a progestin-only oral contraceptive from prescription to 
over-the-counter status.145 Second, the FDA’s decision to deny 
such a proposal or application must constitute a final agency 
action.146 If these requirements were met, the FDA action would be 
subject to judicial review. The plaintiffs’ hypothetical 
constitutional claim would not be reviewed under the same 
standard used in Hamburg, the arbitrary and capricious standard.147 
Because the claim would be a constitutional one, not merely one 
challenging an agency action as was the case in Hamburg, the less 
agency-deferential de novo review would be applicable to 
plaintiffs’ claim.148   
The FDA’s decision to reject a petition allowing over-the-
counter emergency contraception, as discussed in Hamburg, may 
forecast its future actions with respect to a daily birth control 
pill.149 The FDA may again deviate from policy to deny a petition 
                                                          
145 21 U.S.C. § 353(b)(3) (2012); 21 C.F.R. § 10.25(a) (2009); 21 C.F.R. § 
310.200(b) (2009). 
146 5 U.S.C. § 704 (2012). 
147 Id. § 706 (2012). See also Tummino v. Hamburg, 936 F. Supp. 2d 162, 
184 (E.D.N.Y. 2013).  
148 5 U.S.C.A § 706 (2012); George v. United States, 901 F. Supp. 2d 1179, 
1184 (N.D. Cal. 2012) (stating that “[i]t matters not whether the claim is styled 
under the [Administrative Procedure Act] or the Constitution itself,” the same 
standard of review applies in both cases). 
149 See Hamburg, 936 F. Supp. 2d at 170 (“The denial of the [Supplemental 
New Drug Application] and Citizen Petition was accomplished by unexplained 
departures from a number of established policies and practices followed by the 
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as it did for emergency contraception. Such actions by the FDA 
would be highly scrutinized in a hypothetical case.150 In Hamburg, 
Judge Korman mentioned that because “the constitutional right to 
obtain and use contraceptives” was implicated by the restriction on 
the sale of Plan B, “an even more careful examination of [the 
unprecedented intervention of the HHS Secretary]” was 
justified.151 Indeed, a constitutional claim invoking the right to 
contraception would be a next logical step for reproductive rights 
advocates in light of Hamburg. In Hamburg, plaintiffs were 
successful because the FDA’s actions were deemed arbitrary and 
capricious.152 In the context of a daily pill, plaintiffs alleging a 
constitutional claim would enjoy a stricter standard, though any 
similar arbitrary and capricious FDA actions would lend support to 
the constitutional claim.153 Assuming the above procedural 
requirements were satisfied, any decision by the FDA to deny a 
petition or application for an over-the-counter daily birth control 
pill, particularly after Hamburg, has the potential to generate a 
viable constitutional claim.  
 
A. Fifth Amendment Substantive Due Process 
 
Advocates for an over-the-counter progestin-only birth control 
pill may choose to allege a government violation of the Fifth 
Amendment’s substantive due process guarantee. Under this 
framework, plaintiffs would need to first assert government 
infringement on a fundamental right.154 If the right is deemed 
fundamental, the government then bears the burden to show that 
the prescription requirement for a progestin-only oral contraceptive 
is supported by a compelling interest.155 Additionally, the 
                                                          
FDA.”). 
150 See id.  
151 Id. at 186.  
152 Id. at 184.  
153 Id. In Hamburg, section 706(2)(A) applied. This section permits a 
district court to set aside agency actions that are “arbitrary, capricious, an abuse 
of discretion, or otherwise not in accordance with law.” 5 U.S.C. § 706(2)(A).  
154 ERWIN CHEMERINSKY, CONSTITUTIONAL LAW PRINCIPLES AND POLICIES 
814 (Vicki Been et al. eds., 4th ed. 2011).  
155 Id.  
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government must show that the prescription requirement for a 
progestin-only oral contraceptive is narrowly tailored to serve that 
articulated compelling interest.156  
Plaintiffs could argue that the fundamental right to privacy is 
implicated in the prescription requirement for a daily progestin-
only birth control pill. The U.S. Supreme Court’s decisions in 
Griswold v. Connecticut,157 Eisenstadt v. Baird,158 and Carey v. 
Population Services International159 support the assertion that a 
fundamental right is at issue.160 Griswold classified the right to 
contraception as a right imbedded in the right to privacy by 
reasoning that, among married couples, the decision to use 
contraceptives fell within a zone of privacy.161 Afterwards, 
Eisenstadt and Carey expanded and clarified the right to 
contraception.162 In Eisenstadt, the Court extended the right to use 
contraception, encompassed in the right to privacy, to unmarried 
people using an equal protection analysis.163 In doing so, the Court 
re-characterized the right to contraception as a right to procreative 
privacy, rather than simply a right to marital privacy as described 
in Griswold.164 In Eisenstadt, the Court reasoned that, “[i]f the 
right to privacy means anything, it is the right of the individual, 
married or single, to be free of unwarranted governmental intrusion 
into matters so fundamentally affecting a person as the decision 
whether to bear or beget a child.”165 Though it could be argued that 
the right to contraception imbedded in the fundamental right to 
privacy does not necessarily indicate that there is a right to access 
                                                          
156 Id. at 817.  
157 Griswold v. Connecticut, 381 U.S. 479 (1965). 
158 Eisenstadt v. Baird, 405 U.S. 438 (1972). 
159 Carey v. Population Servs. Int’l, 431 U.S. 678 (1977).  
160 These cases have been read to imply that the fundamental right to 
privacy includes the right to use contraception. See CHEMERINSKY supra note 
154, at 837–38 (“[A] basic right, such as the ability to control procreation, is 
constitutionally protected . . . .”). 
161 Griswold, 381 U.S. at 485.   
162 See Carey, 431 U.S. at 701; Eisenstadt, 405 U.S. at 453–55.   
163 Eisenstadt, 405 U.S. at 453. 
164 Id. 
165 Id.  
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contraception, the Court’s decision in Carey is telling.166 There, the 
Court decided that a law limiting the display, advertisement, and 
distribution of contraceptives was unconstitutional and held that 
government restrictions on contraceptive access must meet strict 
scrutiny.167 The Court reasoned that “[t]his is so not because there 
is an independent fundamental ‘right of access to contraceptives,’ 
but because such access is essential to exercise of the 
constitutionally protected right of decision in matters of 
childbearing.”168 Following this line of cases, the Court appears 
willing to include the right to use contraception “free from 
“unjustified intrusion by the state”169 as part of the right to privacy.   
Roe v. Wade170 and Planned Parenthood v. Casey171 also 
provide guidance in this analysis and suggest that a fundamental 
right is implicated in the prescription requirement for a progestin-
only birth control pill. Both cases, though relating to abortion 
rights, suggest that women have fundamental rights concerning 
their reproductive decisions.172 In Roe, the Court determined that 
the “right of privacy . . . is broad enough to encompass a woman’s 
decision whether or not to terminate her pregnancy.”173 It follows 
that a woman’s decision whether or not to prevent pregnancy in the 
first place is also a fundamental right encompassed in the right to 
privacy.174 In Casey, the Court recognized that “choices central to 
dignity and autonomy are central to the liberty [protected by the 
Constitution]” and asserted that, “[a]t the heart of liberty is the 
right to define one’s own concept of existence, of meaning, of the 
                                                          
166 See Carey, 431 U.S. at 697–98. 
167 Id. at 700–02. Strict scrutiny is “the most intensive type of judicial 
review.” CHEMERINSKY, supra note 154, at 554. Under this standard, “the court 
must regard the government’s purpose as vital” and the law must be “the least 
restrictive or least discriminatory alternative” in order for it to be upheld. Strict 
scrutiny is used in cases of “discrimination based on race or national origin,” for 
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168 Carey, 431 U.S. at 688.  
169 Id. at 687.  
170 Roe v. Wade, 410 U.S. 113 (1973). 
171 Planned Parenthood of Southeastern Pa. v. Casey, 505 U.S. 833 (1992).  
172 See Casey, 505 U.S. at 833; Roe, 410 U.S. at 113.    
173 Roe, 410 U.S. at 153. 
174 See id.  
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universe, and of the mystery of human life.”175 Though Roe and 
Casey concern abortion rights, the reasoning used in both cases is 
applicable to the right to contraception as fundamental under the 
right to privacy: women have the right to control their reproduction 
and make autonomous decisions in these matters.176 
The rights to contraceptive access, autonomy, and personal 
dignity have been expressly articulated by the Court.177 Plaintiffs 
challenging the prescription requirement using the Fifth 
Amendment’s substantive due process guarantee should be able to 
articulate a fundamental right at issue. After plaintiffs assert that 
the prescription requirement for a progestin-only oral contraceptive 
implicates the fundamental right to privacy and imbedded right to 
contraception, the burden would then shift to the government.178 
The government must show a compelling interest behind the 
prescription requirement and subsequently show that the regulation 
was narrowly tailored to serve that compelling interest.179  
The FDA would most likely assert that the prescription 
requirement serves the government’s compelling interest in 
protecting women’s health.180 Roe established that “the State [has] 
an important and legitimate interest in preserving and protecting 
the health of the pregnant woman . . . and that it has 
still another important and legitimate interest in protecting the 
potentiality of human life.”181 It is likely that the government’s 
interest in protecting women’s health would be found to be 
sufficiently compelling and would thus satisfy the first prong.182  
                                                          
175 Casey, 505 U.S. at 851.   
176 See id. at 833; Roe, 410 U.S. at 113. 
177 See, e.g., Casey, 505 U.S. at 833; Eisenstadt v. Baird, 405 U.S. 438 
(1972). 
178 See CHEMERINSKY, supra note 154, at 817.   
179 See id.  
180 Roe, 410 U.S. at 162.   
181 Id.  
182 The Court in Roe also mentioned a government interest in “maintaining 
medical standards.” Roe, 410 U.S. at 154–55. It stated, “[t]he State has a 
legitimate interest in seeing to it that abortion, like any other medical procedure, 
is performed under circumstances that insure maximum safety for the patient. 
This interest obviously extends at least to the performing physician and his staff, 
to the facilities involved, to the availability of after-care, and to adequate 
provision for any complication or emergency that might arise.” Id. at 149–50. 
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If a court determined that the government had a compelling 
interest in women’s health, the FDA would have the burden to 
show that the prescription requirement for progestin-only oral 
contraceptives was narrowly tailored to serve that interest.183 The 
government would be unable to show that the prescription 
requirement is narrowly tailored to serve its compelling interest. 
The prescription requirement is over-inclusive in that it applies to 
all women, rather than exclusively to the small percentage of 
women with contraindications to a progestin-only pill.184 For other 
drugs, the FDA addresses similar concerns about contraindications 
in a small subset of the population through labeling, not by 
excluding these drugs from over-the-counter distribution.185 
Although women who obtain a prescription for a progestin-only 
oral contraceptive would be afforded the opportunity to consult 
with their healthcare provider regarding their decision to use this 
method of contraception, evidence shows that technology within 
pharmacies could provide the same level of guidance.186 Women 
are able to assess their own need to use oral contraceptives and 
regardless of whether women consult with a physician, the daily 
administration of the pill is left in their hands. Healthcare providers 
determine whether a woman should be prescribed birth control, 
especially a progestin-only pill, almost entirely by hearing a 
recitation of the woman’s medical history. Women could just as 
easily read labels that explain contraindications, as they are asked 
to do with other FDA-approved over-the-counter products, and 
then make an informed decision about whether or not to take the 
                                                          
The government could use this line of reasoning to argue that the prescription 
requirement serves its interest of maintaining such standards by ensuring that 
doctors act as gatekeepers to oral contraception that could be dangerous for 
some women.  
183 See CHEMERINSKY, supra note 154, at 817.   
184 “[A] classification that is substantially overinclusive or underinclusive 
tends to undercut the governmental claim that the classification serves 
legitimate” purposes. Bernal v. Fainter, 467 U.S. 216, 221 (1984) (citation 
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185 See Tummino v. Hamburg, 936 F. Supp. 2d 162, 180 (E.D.N.Y. 2013). 
For example, the FDA relies on labeling, rather than point-of-sale or age 
restrictions, for certain drugs that may be dangerous for younger users, in order 
to allow these products to be available over the counter. Id.  
186 FDA Public Hearing 2012, supra note 27, at 39. 
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pill.187   
In addition, emerging technology could improve the safe 
distribution of an over-the-counter pill, further undermining the 
government’s argument that the prescription requirement is 
narrowly tailored to protect women’s health. One example is that 
women could use the kiosk system, discussed above in Part I.C., to 
input their health histories and undergo screenings for 
contraindications as well as subsequently consult with a pharmacist 
in the same location where they would obtain the pill. Regarding 
these kiosks, clearly and carefully worded questions, a private 
comfortable setting, as well as features for non-English speakers 
and individuals with limited literacy have the potential to not only 
meet, but improve the accuracy and thoroughness of the medical 
history information given by a woman seeking oral contraception. 
In this manner, emerging technology could be used to provide 
convenient and safe access to oral contraceptives.  
The prescription requirement for birth control pills ultimately 
results in more health risks and poorer health outcomes for women 
than they would face in the absence of such a requirement.188 This 
is perhaps the strongest argument as to why the prescription 
requirement for a progestin-only birth control pill is not narrowly 
tailored to serve the government’s interest in protecting women’s 
health. As suggested above, there is also substantial evidence to 
suggest that oral contraceptives actually improve a woman’s health 
by, for example, lowering her risk of contracting endometrial 
cancer and pelvic inflammatory disease.189   
Aborting a pregnancy or carrying a pregnancy to full term both 
pose higher risks for a woman’s health than using oral 
contraception.190 Unintended pregnancies, many of which could be 
                                                          
187 The FDA has established the practice of relying on labeling to inform 
consumers and allow drugs to be sold over-the-counter. Hamburg, 936 F. Supp. 
2d at 173.  
188 See, e.g., Logan et al., supra note 45, at 1, 5, 7. 
189 See, e.g., Mini-Pills, supra note 32; Oral Contraceptives and Cancer 
Risk, NAT’L CANCER INST., http://www.cancer.gov/cancertopics/factsheet/ 
Risks/oral-contraceptives (last visited Oct. 18, 2013). 
190 See Genevra Pittman, Abortion Safer than Giving Birth: Study, REUTERS 
(Jan. 23, 2012), http://www.reuters.com/article/2012/01/23/us-abortion-
idUSTRE80M2BS20120123; Facts on Induced Abortion, supra note 42, at 2. 
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prevented with greater availability of oral contraceptives, are 
especially risky for a woman’s health because women experiencing 
an unplanned pregnancy are less likely to seek appropriate prenatal 
care.191 Also, “[w]omen with unwanted, mistimed, or unplanned 
births demonstrate lower levels of general psychological well-
being during pregnancy and following the birth, and a higher risk 
of depression . . . .”192 For children born as a result of these 
pregnancies, “unintendedness seems to be most closely associated 
with poor physical health, poor mental health, a less close mother-
child relationship, and poor educational outcomes.”193 Moreover, 
unintended pregnancies resulting in births produce high costs to 
society as a whole.194  Considering the possible health benefits of 
birth control, the dangers of unplanned pregnancies, and the 
emergence of technology to provide safeguards to over-the-counter 
distribution, the prescription requirement is not narrowly tailored 
to serve the government’s interest in protecting women’s health.  
The hypothetical plaintiffs would likely be able to show that 
the prescription requirement infringes on the fundamental right to 
privacy under the substantive due process guarantee.195 While the 
government would plausibly be able to show a compelling interest 
in maintaining the prescription requirement for progestin-only oral 
contraceptives, the government could not demonstrate how the 
requirement was narrowly tailored to protect women’s health. 
Plaintiffs would thus have a viable chance of success in alleging a 
Fifth Amendment substantive due process violation present in the 
prescription requirement for a progestin-only pill. 
 
B. Classification-Based Equal Protection  
 
A challenge to the prescription requirement for a progestin-
only oral contraceptive could also be brought under the equal 
                                                          
Though first trimester abortions pose minimal risks, “[t]he risk of death 
associated with abortion increases with the length of pregnancy . . . .”  Id. 
191 Logan et al., supra note 45, at 1, 3.   
192 Id. at 8.  
193 Id. at 5–6.  
194 Id. at 1, 6, 8; McIntosh et al., supra note 43, at 424. 
195 See Carey v. Population Servs. Int’l, 431 U.S. 678 (1977); Eisenstadt v. 
Baird, 405 U.S. 438 (1972); Griswold v. Connecticut, 381 U.S. 479 (1965). 
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protection clause of the Fourteenth Amendment.196 Unlike the 
substantive due process clause, the equal protection clause does not 
create substantive individual rights.197 Rather, the equal protection 
clause asks whether the government has a sufficient purpose in 
imposing a law that classifies and distinguishes between groups of 
people.198 When regulations are facially neutral, as is the case with 
the prescription requirement for a progestin-only pill, the plaintiff 
must show that the law has both a disparate impact and a 
discriminatory purpose.199  
 
1. Gender Classification Claim 
 
In equal protection cases alleging classification based on 
gender, intermediate scrutiny200 is used.201 Under intermediate 
scrutiny, if the law at issue is facially neutral as is the prescription 
requirement, the plaintiffs must articulate that the law is 
purposively discriminatory and that the law has a discriminatory 
effect on males or females.202 Then, the burden shifts to the 
government to show that the regulation at issue is “substantially 
related to serving an important government purpose.”203  
The prescription requirement is facially neutral because it does 
not explicitly classify men and women. Therefore, plaintiffs have 
the burden of showing both that the prescription requirement has a 
disparate impact on women, and there is a discriminatory purpose 
                                                          
196 See Bolling v. Sharpe, 347 U.S. 497, 498–99 (1954). The Court reads 
the Fifth Amendment due process clause to include the equal protection 
guarantee of the Fourteenth Amendment. Id. 
197 See CHEMERINSKY, supra note 154, at 685.   
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Boren, 429 U.S. 190 (1976). 
202 CHEMERINSKY, supra note 154, at 777.   
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behind it.204 The disparate impact of the prescription requirement is 
evident: only women use oral contraception and therefore are the 
only sex subjected to the prescription requirement.  
Plaintiffs also have a strong argument that there is a 
discriminatory purpose behind the prescription requirement. In 
Village of Arlington Heights v. Metropolitan Housing Development 
Corp.,205 the Court identified different ways plaintiffs could 
demonstrate a discriminatory purpose.206 A discriminatory purpose 
can be shown by a historical pattern of discrimination, statistical 
patterns that can only be explained by discrimination, and 
legislative or administrative history that points toward 
discrimination.207 Here, plaintiffs have a number of arguments at 
their disposal. First, plaintiffs could point to the historical 
discrimination of women in general. Additionally, plaintiffs could 
cite reports showing that virtually every part of the required 
doctor’s visit in order to obtain a prescription is unnecessary to 
determine whether a progestin-only birth control pill would be safe 
for use.208 Plaintiffs could also reference statistics that women 
could easily use available technology and informative labeling to 
safely take a progestin-only oral contraceptive.209  
In proving a discriminatory purpose, plaintiffs can also rely on 
evidence that the FDA has a history of discriminating against 
women’s rights to access contraception.210 Plaintiffs could 
specifically point to the FDA’s unusual action to delay, and 
eventually deny, over-the-counter emergency contraception for 
females of all ages as evidence of the FDA’s discriminatory 
motivation in thwarting attempts to expand the availability of oral 
                                                          
204 Id. at 777.  
205 Vill. of Arlington Heights v. Metro. Hous. Dev. Corp., 429 U.S. 252, 
266–68 (1977).  
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209 FDA Public Hearing 2012, supra note 27, at 48–49. See also McIntosh 
et al., supra note 43, at 430. 
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contraceptives.211  In fact, the FDA has a long history of taking 
unusual actions to delay and prevent expanded access to oral 
contraceptives for women.212  For example, the initial Plan B 
prescription to over-the-counter switch application was the only 
one of sixty-seven applications filed between 1994 and 2004 not to 
be approved after advisory committees recommended approval.213 
In Hamburg, Judge Korman identified a plethora of features of 
the FDA’s decision-making process that rendered the denial of the 
citizen petition unprecedented.214 For example, HHS Secretary 
Sebelius cited “cognitive and behavioral differences between older 
adolescent girls and the youngest girls of reproductive age” as a 
reason to direct the FDA to deny the petition for over-the-counter 
access for females of all ages.215 However, normally the FDA does 
not rest its decisions about whether to switch a drug from 
prescription to over-the-counter on “theoretical abuse by a very 
small segment of the population.”216 If the FDA did, then it would 
be required to stop selling any “drugs with known abuses” over the 
counter, including “laxatives because of abuse by people suffering 
from bulimia” and “acetaminophen because of its use in 
                                                          
211 See Hamburg, 936 F. Supp. 2d at 168; Von Eschenbach, 427 F. Supp. 
2d at 228–29. 
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suicides.”217 Hypothetical plaintiffs could use this kind of evidence 
to show that a discriminatory purpose underlies the prescription 
requirement for progestin-only pills. The plaintiffs have support 
that the FDA’s “administrative history [is] highly relevant” to a 
determination of discriminatory purpose.218  
If plaintiffs are successful in proving disparate impact and 
purposeful discrimination, then the government must make two 
showings. First, the government must show that the prescription 
requirement serves an important objective.219 Second, the 
government must show that the means of the classification are 
substantially related to the achievement of that important 
governmental objective.220   
The Court’s decision in Cleveland Board of Education v. 
LaFleur may be instructive to plaintiffs challenging the 
prescription requirement for a progestin-only birth control pill. In 
LaFleur, the Court declared that a school board requirement that 
pregnant employees take maternity leave at a fixed time in their 
pregnancies was unconstitutional.221 The Court reasoned that the 
regulation amounted “to a conclusive presumption that every 
pregnant teacher who reaches the fifth or sixth month of pregnancy 
is physically incapable of continuing” to teach.222 Plaintiffs 
challenging the prescription requirement for a progestin-only birth 
control pill could make a similar argument that the prescription 
requirement does not serve an important governmental interest. 
Just as the Cleveland Board of Education’s maternity leave 
requirement did not substantially serve its articulated interest, 
promoting educator continuity in instruction,223 the prescription 
requirement for a progestin-only birth control pill does not 
substantially serve the government’s alleged interest in protecting 
women’s health. In LaFleur, the Court assumed that all pregnant 
teachers are unable to continue working at a board-determined 
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time in their pregnancy.224 Here, the prescription requirement rests 
on an agency-determined assumption that women need an 
incentive, in this case a birth control prescription, to seek 
preventative medical care.225 Both the  requirement in LaFleur and 
the prescription requirement for a progestin-only birth control pill 
seem to further the belief that agencies and boards understand the 
needs and psyche of all women better than an individual woman 
can make autonomous decisions in her own health-related matters.  
In later cases, the Court clarified its holding in LaFleur. The 
Court explained that the government’s “justification must be 
genuine, not hypothesized or invented post hoc in response to 
litigation. And it must not rely on overbroad generalizations about 
the different talents, capacities, or preferences of males and 
females.”226 The Court further declared that in classifying on the 
basis of sex, the government must demonstrate an “exceedingly 
persuasive” justification for the action.227 Even if the government 
can pass the high hurdle in asserting an important interest behind 
the requirement, the government must still show that the means of 
the requirement are substantially related to the achievement of that 
interest.228  
Using this framework, hypothetical plaintiffs could challenge 
the government’s asserted interest in women’s health. Protecting 
the health of women was likely the government’s actual objective 
in requiring a prescription for progestin-only oral contraception. 
However, a mounting body of evidence suggests that a progestin-
only pill could be safely dispensed over the counter.229 This 
evidence, plaintiffs could assert, suggests that the women’s health 
objective may indeed be a post hoc rationalization for maintaining 
the prescription requirement when the progestin-only pill has been 
considered safe for quite some time. 
The government may choose to supplement its articulated 
purpose of protecting women’s health. It could assert that the 
                                                          
224 See id.  
225 See Trussell et al., supra note 2, at 1095.   
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228 Craig v. Boren, 429 U.S. 190, 197 (1976). 
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prescription requirement gives women a needed incentive to have 
regular annual exams, even though these exams have little to do 
with a doctor’s determination that a patient can safely take a 
progestin-only pill.230 However, the U.S. Preventative Services 
Task Force and the American Cancer Society now discourage 
annual pap tests in favor of less frequent tests depending on a 
woman’s age, risk factors, and prior screening results.231 Though it 
might in fact be the case that women who would otherwise forgo 
annual exams submit to them in order to obtain a birth control 
prescription, this paternalistic rationalization cannot meet the 
government’s burden.  
The government may also rely on an “overbroad 
generalization” by assuming that all women desire direct 
communication with their doctor, a physical examination, and 
prescription before choosing to use oral contraception.232 Evidence 
suggests that given the inconvenience and expense of doctor’s 
visits, coupled with women’s ability to use emerging technology to 
safely make a decision, many women would prefer an over-the-
counter birth control pill.233 Thus, though the government’s 
objective of protecting women’s health is indeed important, the 
government would likely be unable to provide the required 
“exceedingly persuasive justification”234 for the prescription 
requirement.  
Even if the government did have a sufficiently important 
interest in protecting women’s health, its means are not 
substantially related to that interest. As discussed above, the 
barriers the prescription requirement generates actually pose health 
risks to women.235 Oral contraceptives have numerous health 
benefits and unintended pregnancies can pose serious health risks 
for both the mother and child.236 There is indeed an alternative to 
the current oral contraceptive prescription regime that would 
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enable greater access to birth control for women while ensuring 
their safety.237 As explained above, estrogen-progestin 
combination pills have more contraindications than progestin-only 
contraceptives.238 By maintaining the prescription requirement for 
estrogen-progestin pills while making a progestin-only pill 
available over the counter, women would no longer be subjected to 
unnecessary paternalistic barriers hindering access to oral 
contraception.  
Thus, plaintiffs would likely be able to show that the facially 
neutral prescription requirement has both a discriminatory impact 
on women and is purposively discriminatory. The government may 
have difficulty showing that its interest in women’s health is not a 
post hoc rationalization for the maintenance of the prescription 
requirement and that the requirement is not based on overbroad 
generalizations. However, the government may be able to meet the 
first of its burdens to show that there is an important interest—the 
protection of women’s health—behind the prescription 
requirement. However, the government would likely be unable to 
show that the prescription requirement substantially serves its 
interest in women’s health. Plaintiffs may therefore have success in 
pursuing a gender classification-based equal protection violation 
claim.   
 
2. Other Classification-Based Equal Protection Claims 
 
As discussed above, access issues imposed by the prescription 
requirement for progestin-only oral contraceptives 
disproportionately affect minority women, young women, and low-
income women as evidenced by the high instances of unintended 
pregnancies among these groups.239 Plaintiffs may therefore 
choose to challenge other classifications imposed by the 
prescription requirement. Because the prescription requirement is 
facially neutral, to allege an impermissible classification based on 
race or national origin, plaintiffs would have to make two 
                                                          
237 See id.   
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showings to subject the classification to heightened scrutiny.240 
First, they would need to show that the prescription requirement 
has a disproportionate impact on a racial or ethnic group. Second, 
plaintiffs would need to show the there is a discriminatory purpose 
underlying the prescription requirement.241 Any wealth and age 
classification claims brought by the plaintiffs challenging the 
prescription requirement would be subject only to rational basis 
review.242  
In regards to race, national origin, and alienage, plaintiffs could 
likely show the disparate impact of the prescription requirement. 
They could assert, for example, that African-American women 
experience significantly more unintended pregnancies than any 
other racial group in the country and are more likely than white 
women to have gaps in contraceptive use.243 Though they may 
meet the requirements for disparate impact, plaintiffs would be 
challenged to show that there is a racially discriminatory purpose 
behind the prescription requirement. In Washington v. Davis,244 the 
Court upheld a police officer promotion test that had a higher 
passage rate among white employees than black employees. The 
Court reasoned that without evidence of a discriminatory purpose, 
a regulation that disparately impacts a racial group will be subject 
only to rational basis review.245 Unlike a potential gender 
classification claim where the requirement applied only to women, 
                                                          
240 Washington v. Davis, 426 U.S. 229, 242 (1976). Heightened scrutiny is 
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and not men, the prescription requirement applies to women of all 
races. Therefore, the government would be able to show that it 
would have imposed the same requirement without the alleged 
impermissible racial purpose.246   
Because plaintiffs could not produce sufficient evidence of a 
discriminatory purpose related to race or national origin and the 
Court has expressly articulated that wealth and age classifications 
are subject only to rational basis review, claims based on race, 
national origin, alienage, wealth, or age would not be subject to 
heightened scrutiny.247 The prescription requirement would be 
upheld under rational basis review since the government would be 
able to show that protecting women’s health is, in fact, a legitimate 
purpose and that the requirements had a rational relation to that 
legitimate government purpose.248 Because the prescription 
requirement allows doctors to make the determination about 
whether an oral contraceptive would be safe for an individual 
patient, a court would likely hold that the prescription requirement 
for a progestin-only birth control pill is rationally related to 
protecting women’s health. Such a holding would occur despite the 
fact that the prescription requirement is over-inclusive and that the 
women’s health objective may not be the actual purpose in the 
long-time maintenance of the prescription requirement for 
progestin-only oral contraceptives. Therefore, in bringing an equal 
protection violation claim, plaintiffs would only have a viable 
chance of success in asserting an impermissible classification on 




The prevalence of unintended pregnancies and the negative 
consequences that accompany these pregnancies necessitates 
efforts to reduce barriers to contraceptive access.249 Though oral 
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contraceptives are one of the most effective and widely used 
contraceptive methods, the prescription requirement makes the 
process of obtaining birth control pills unnecessarily difficult.250 
As evidenced by the over-the-counter approval process the FDA 
employed for Plan B emergency contraception, the FDA will likely 
continue its practices of delaying and denying expanded access to 
oral contraception.251 Indeed, the politics surrounding birth control, 
rather than the health risks associated with such drugs, prevents 
women from exercising their full constitutional right to use 
contraception.  
Thus, plaintiffs would be able to make a strong showing that 
the prescription requirement for progestin-only oral contraceptives 
is in fact unconstitutional. Though the right to contraception has 
been recognized since the 1960s, increased safety, improved 
technology, and the known health benefits of oral contraceptives 
have not been adequately considered to fully realize the benefits of 
contraceptive use in today’s society.252 The prescription 
requirement for a progestin-only oral contraceptive indicates that 
our nation’s long history of female subordination and paternalism 
of women has not been wholly abolished.253 The elimination of the 
prescription requirement would therefore serve the goals of gender 
equality and a full recognition of the modern right to 
contraception. It would also address the prevalence of unintended 
pregnancies and the negative implications of these pregnancies on 
women, children, and society as a whole.254 Safety concerns, 
politics, and paternalistic rationales supporting the maintenance of 
the prescription requirement for the pill are facing ever-growing 
scrutiny by the courts, medical associations, and by the public at 
large. Eliminating the prescription requirement for a progestin-only 
oral contraceptive would give women the ability to more fully 
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control their own birth control decisions. 
